Good
Mostly Aligned
Patient Risk:
Low
Summary
Most neuropsychiatric boxed-warning/precaution details and actions (monitoring, discontinue and immediate contact, seriousness including suicidal thoughts/behavior, and possible persistence) are consistent with label content in Warnings and Precautions (5.1) and Patient Counseling (17). Several broader statements are not directly supported by the supplied label excerpts (e.g., “FDA requires a boxed warning,” and specific inclusions in the boxed warning list).
Category Scores
Accurate Statements
Serious neuropsychiatric events have been reported with SINGULAIR.
Supported by Label 5.1 (Neuropsychiatric Events: serious NP events have been reported).
Neuropsychiatric events reported include suicidal thoughts or behavior (including suicide).
Supported by Label 5.1 listing 'suicidal thoughts and behavior (including suicide)'.
Reports include agitation, aggressive behavior or hostility, depression, sleep problems/insomnia, abnormal dreams/dream abnormalities, hallucinations.
Supported by Label 5.1 list (agitation; aggressive behavior or hostility; depression; insomnia; dream abnormalities; hallucinations).
Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder.
Supported by Label 5.1 sentence 'reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder'.
Clinicians and patients/caregivers should discuss benefits and risks and be alert for changes in behavior or new neuropsychiatric symptoms.
Supported by Label 5.1 ('Discuss the benefits and risks...' and 'Advise patients and/or caregivers to be alert for changes in behavior or for new NP symptoms...').
If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, patients should discontinue SINGULAIR and contact a healthcare provider immediately.
Supported by Label 5.1 ('advise patients to discontinue SINGULAIR and contact a healthcare provider immediately').
Symptoms may resolve after stopping, but in some cases symptoms persisted after discontinuation; continue monitoring and supportive care until symptoms resolve.
Supported by Label 5.1 (explicit persistence statement and 'continue to monitor and provide supportive care until symptoms resolve').
Unsupported Statements
The FDA requires a boxed warning for montelukast due to serious neuropsychiatric side effects.
The supplied prescribing information excerpts provided do not include any boxed warning text or confirm that the warning is boxed.
Montelukast boxed warning includes agitation.
The supplied excerpts describe neuropsychiatric events in Warnings and Precautions (5.1), but they do not establish these items as part of a boxed warning specifically.
Montelukast boxed warning includes aggression.
Same issue: label excerpt provided does not confirm boxed-warning itemization.
Montelukast boxed warning includes depression.
Same issue: label excerpt provided does not confirm boxed-warning itemization.
Montelukast boxed warning includes sleep problems.
Same issue: label excerpt provided does not confirm boxed-warning itemization (though insomnia is listed in 5.1).
Montelukast boxed warning includes abnormal dreams.
Same issue: label excerpt provided does not confirm boxed-warning itemization (though dream abnormalities are listed in 5.1).
Montelukast boxed warning includes hallucinations.
Same issue: label excerpt provided does not confirm boxed-warning itemization.
Montelukast boxed warning includes suicidal thoughts or actions.
Same issue: label excerpt provided does not confirm boxed-warning itemization.
The FDA action was based on reports of neuropsychiatric events in patients taking montelukast.
The supplied excerpts do not describe regulatory rationale or 'FDA action' basis.
The FDA warns that montelukast can cause these neuropsychiatric effects in some people.
The supplied excerpts state serious NP events have been reported and advise risk-benefit considerations; they do not directly use the causal phrasing 'can cause' in the provided text.
Clinicians and patients should monitor closely after starting montelukast.
The label advises patients/caregivers to be alert for changes and to monitor/support until symptoms resolve; the specific instruction 'monitor closely after starting' is not directly stated in the provided excerpts.
The FDA warning directs prompt medical attention if mood or behavior changes occur while taking montelukast.
Label 5.1 instructs to discontinue and contact a healthcare provider immediately if changes/new NP symptoms or suicidal thoughts/behavior occur; 'prompt medical attention for mood/behavior changes' is a less precise paraphrase than the label requirement.
The FDA warning directs prompt medical attention if sleep disturbances occur while taking montelukast.
Label includes insomnia/dream abnormalities among reported events and provides general discontinuation/contact guidance, but does not give a sleep-specific prompt-medical-attention instruction in the provided excerpts.
The FDA warning directs prompt medical attention if thoughts of self-harm occur while taking montelukast.
Label specifies suicidal thoughts/behavior triggering discontinuation and immediate provider contact; 'self-harm' phrasing is not used in the provided excerpt.
The FDA warning states patients should contact their prescriber right away if symptoms occur rather than waiting for symptoms to resolve.
Label 5.1 advises to discontinue and contact immediately; it does not explicitly address not waiting for resolution.
The FDA warning applies to the montelukast drug class/molecule and therefore carries over to generic montelukast products as well.
The supplied excerpts do not discuss generic carryover or applicability beyond the labeled product.
The boxed warning is part of the labeling for montelukast.
The supplied excerpts do not confirm a boxed warning is included in the provided labeling text.
Contradictions
Important Omissions
Label includes specific reserve/indication limitation language for allergic rhinitis (reserve for inadequate response/intolerance to alternative therapies) and benefit-risk consideration language for asthma/exercise-induced bronchoconstriction before prescribing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response’s core safety actions around neuropsychiatric monitoring, discontinuation, and immediate provider contact for behavioral/neuropsychiatric changes including suicidal thoughts/behavior are aligned with label guidance (5.1 and 17). However, several statements overgeneralize/attribute details to a boxed warning and include phrasing not directly supported by the provided label excerpts, which could affect interpretation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some items attribute neuropsychiatric event lists and regulatory statements specifically to a 'boxed warning' without support from the provided label excerpts.
Suggested Improvement
Rephrase the claims to match the label text in Warnings and Precautions (5.1) without asserting boxed-warning inclusion (unless the boxed-warning section is provided/verified), and align monitoring wording to the label’s 'be alert' and discontinuation/immediate contact instructions.